Clinical Trials
9
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 467
- Registration Number
- NCT04971109
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Advanced Pharma, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Study to Assess the Safety and Pharmacokinetics of TPOXX® When Administered Orally for 28 Days With JYNNEOS
- Conditions
- Smallpox
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 100
- Registration Number
- NCT04957485
- Locations
- 🇺🇸
Meridian Clinical Research, Omaha, Nebraska, United States
🇺🇸Aventiv Research Inc, Columbus, Ohio, United States
Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
- Conditions
- Smallpox
- Interventions
- Drug: sucroferric oxyhydroxide chewable tablet
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 44
- Registration Number
- NCT04485039
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 34
- Registration Number
- NCT04392739
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox
- Conditions
- Smallpox
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- SIGA Technologies
- Registration Number
- NCT03972111
- Locations
- 🇺🇸
Investigator Site, Corvallis, Oregon, United States
- Prev
- 1
- 2
- Next
News
Kenox and Lactiga Partner to Develop First-in-Class Mucosal Immunotherapy for Immunodeficient Patients
Kenox Pharmaceuticals and Lactiga have formed a strategic collaboration to develop novel secretory IgA (sIgA) therapies for immunodeficient patients, supported by a multi-million-dollar NIAID grant.
Tecovirimat (TEPOXX) Approved in Japan for Orthopoxvirus Infections
The Japan Ministry of Health, Labour and Welfare has approved tecovirimat (TEPOXX) for treating smallpox, mpox, cowpox, and smallpox vaccination complications.
Tecovirimat Fails to Improve Mpox Outcomes in NIH-Sponsored STOMP Trial
The STOMP trial found that tecovirimat did not significantly reduce lesion resolution time or pain in adults with mild to moderate mpox.